Trump’s return to the White House will mean a shift in personnel at the US Federal Trade Commission (FTC), which could mean more biopharmaceutical M&A deal activity in the country, an analyst ...

After a drawn-out acquisition that closed in 2023, U.K. biotech F-star Therapeutics is charting its own path as a private, ...

Partnership bolsters Boehringer’s autoimmune and inflammatory disease pipeline portfolio aiming to tackle areas of high unmet patient ...

Appointed John H. Johnson as Executive Chairman; Todd F. Baumgartner, MD, MPH as Chief Regulatory Officer; and Reena Thomas Colacot as Vice ...

Protagonist Therapeutics, Inc. (”Protagonist” or the “Company”), a clinical-stage biopharmaceutical company pioneering the discovery and development of peptide-based therapeutics, today announced that ...

B. subtilis spores are stable across a wide temperature range, which reduces the cost of storage and transportation.

KLP Kapitalforvaltning AS bought a new stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Free Report) in the ...

Dr. Reid Bissonnette, Executive Consultant for Translational Research and Development at Xenetic, discusses positive preclinical data recently presented at the Society for Immunotherapy of Cancer ...

ClearBridge Investments, an investment management company, released its “ClearBridge Small Cap Growth Strategy” first quarter 2025 investor letter. A copy of the letter can be downloaded here. The ...

Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the ...